mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    328
  • sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
Updated on 13 May 2022

Summary

A multicenter,open,prospective randomized controlled trial;11 study center in China; Plan to enroll 328 patients( Power Analysis and Sample Size ).Comparing FOLFIRI with mFOLFOX6,Superiority design.Investigate difference PFS,ORR,R0 resection rate,OS ,QoL and Safety from two regimens Stratification factors : Analyzing patients recurrence within 6-12months,and 12-18months .Obtain definite chemotherapy regimen shift opportunity for patients recurrence/metastasis after adjuvant chemotherapy.

Details
Condition Metastatic Colorectal Cancer
Treatment FOLFIRI
Clinical Study IdentifierNCT05362617
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on13 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

-75 years,male or female Colorectal adenocarcinoma Accepting more than 4 cycles oxaplatin
based adjuvant chemotherapy after radical operation Reccurrence in 6-18 months after
adjuvant chemotherapy At least one assessable lesions No intestinal obstruction ECOG 0-1
Estimated survival≥ 3 months CBC:WBC>4×109/L,PLT>80×109/L,Hb>90g/L, Liver function:ALT or
AST < 2× normal maximum value, T-bile<1.5× normal maximum value without hepatic metastatic,
ALT or AST < 5× normal maximum value, T-bile<1.5× normal maximum value with hepatic
metastatic Cr<1.8mg/dl Signed informed consent

Exclusion Criteria

Locally resectable lesions Grade 2-4 oxaliplatin induced neurotoxicity Arrhythmias,coronary
heart disease,or congestive heart failure(NYHA≥grade 2) requiring treatment Poorly
controlled hypertension HIV infected or active HBV or HCV infected Active serious infection
Cachexia or organ function decompensation Multiple primary carcinoma except carcinoma in
situ of skin and cervix Participate in other clinical studies at the same time Serious
heart or brain disease Drug abuse or other serious psychosocial diseases Suspected trial
drug allergy Other factors affecting patient safety and compliance Pregnant or lactating
women,or fertility without adequate contraceptive measures
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note